Abstract:Objective: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy. Data sources: This review was based on a comprehensive search using online literature databases, including PubMed, Web of Science, and Google Scholar. Study selection: Literature search was based on the following keywords: Alzheimer's disease, tau protein, biomarker, cerebrospinal fluid (CSF), therapeutics, plasma, imaging, propagation, spreading, seeding, prion, conformational templating, and posttranslational modification. Relevant articles were carefully reviewed, with no exclusions applied to study design and publication type. Results: Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD. Although the Aβ hypothesis has dominated AD research for many years, clinical Aβ-targeting strategies have consistently failed to effectively treat AD or prevent AD onset. The research focus in AD has recently shifted to the role of tau in AD. In addition to phosphorylation, tau is acetylated and proteolytically cleaved, which also contribute to its physiological and pathological functions. Emerging evidence characterizing pathological tau propagation and spreading provides new avenues for research into the molecular and cellular mechanisms underlying AD pathogenesis. Techniques to detect tau at minute levels in CSF and blood have been developed, and improved tracers have facilitated tau imaging in the brain. These advances have potential to accurately determine tau levels at early diagnostic stages in AD. Given that tau is a potential therapeutic target, anti-tau immunotherapy may potentially be a viable treatment strategy in AD intervention. Conclusion: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.

Tau in the Pathophysiology of Parkinson’s Disease

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Tau in neurodegenerative disease

Tau Protein: Relevance to Parkinson'S Disease

Tau accelerates -synuclein aggregation and spreading in Parkinson's disease

Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration

The role of tyrosine hydroxylase–dopamine pathway in Parkinson's disease pathogenesis

Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

Tau knockout exacerbates degeneration of parvalbumin‐positive neurons in substantia nigra pars reticulata in Parkinson's disease‐related α‐synuclein A53T mice

The role and mechanism of abnormal accumulation and transmission of alpha-synuclein in the pathogenesis and progression of Parkinson′s disease

Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype

alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: mutations, propagation, aggregation, and the formation of inclusions

α-Synuclein and Its Probable Mechanisms in Pathogenesis of Parkinson's Disease

Tau in Health and Neurodegenerative Diseases

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

Navigating the Neurobiology of Parkinson's: The Impact and Potential of α-Synuclein

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease